ANTIGEN PRESENTATION--MODEL OF ALLERGIC EYE DISEASE
Project Number3R01EY012523-02S1
Contact PI/Project LeaderONO, SANTA JEREMY
Awardee OrganizationSCHEPENS EYE RESEARCH INSTITUTE
Description
Abstract Text
Immediate hypersensitivity or allergy is the most widespread
immunological disorder in humans. We have recently developed a mouse
model of allergic conjunctivitis to cat dander (Fel dl), and
characterized the T helper responses in susceptible animals.
Approximately 25% of the world's population suffer from allergies; with
ocular symptoms contributing a significant proportion of the discomfort
and patient care costs associated with allergic disease. There is
considerable interest among ophthalmologists for the development of new
anti-allergic and anti-inflammatory compounds that can be used safely in
the eye. A novel and promising approach to management of ongoing
allergic disease is that of peptide immunotherapy. Identification of
defined T cell epitopes containing peptides, based on the primary
structure of major allergens may provide an effective tool for
modification of human immediate hypersensitivity to allergens. Since
functional and biochemical studies have demonstrated that the generation
of T cell responses depends upon antigen receptors on T cells (TCR)
recognizing peptide fragments of foreign proteins associated with
products of the major histocompatibility complex (MHC), that are
expressed on the membranes of accessory cells, any examination of T cell
epitopes must also include MHC analysis. Therefore, the goal of this
proposal is to use our mouse model of allergic conjunctivitis to clearly
define the molecular interaction in the ternary complex of
immunodominant peptide, the MHC on the antigen presenting cell (APC),
and the T cell receptor. After we have define the specific T
cell/peptide/APC interaction, we will use this information to develop a
novel T cell vaccine my making an antigenized MHC-Ig chimera, and then
to test this T cell vaccine in our mouse model of allergic
conjunctivitis.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
MHC class II antigenT cell receptorT lymphocyteantigen presentationantigen presenting cellchimeric proteinsconjunctivitisdisease /disorder modelhypersensitivityimmunoconjugatesimmunotherapylaboratory mouseleukocyte activation /transformationtissue /cell culturevaccine developmentvaccines
No Sub Projects information available for 3R01EY012523-02S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3R01EY012523-02S1
Patents
No Patents information available for 3R01EY012523-02S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3R01EY012523-02S1
Clinical Studies
No Clinical Studies information available for 3R01EY012523-02S1
News and More
Related News Releases
No news release information available for 3R01EY012523-02S1
History
No Historical information available for 3R01EY012523-02S1
Similar Projects
No Similar Projects information available for 3R01EY012523-02S1